67 related articles for article (PubMed ID: 23344713)
1. All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer.
Tawfik H; Rostom Y; Elghazaly H
Cancer Chemother Pharmacol; 2013 Apr; 71(4):913-9. PubMed ID: 23344713
[TBL] [Abstract][Full Text] [Related]
2. All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial.
Tubiana-Mathieu N; Bougnoux P; Becquart D; Chan A; Conte PF; Majois F; Espie M; Morand M; Vaissiere N; Villanova G
Br J Cancer; 2009 Jul; 101(2):232-7. PubMed ID: 19584872
[TBL] [Abstract][Full Text] [Related]
3. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer.
Pallis AG; Boukovinas I; Ardavanis A; Varthalitis I; Malamos N; Georgoulias V; Mavroudis D
Ann Oncol; 2012 May; 23(5):1164-1169. PubMed ID: 21937705
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane.
Ahn JH; Kim SB; Kim TW; Ahn SH; Kim SM; Park JM; Lee JS; Kang YK; Kim WK
J Korean Med Sci; 2004 Aug; 19(4):547-53. PubMed ID: 15308846
[TBL] [Abstract][Full Text] [Related]
5. A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial.
Baselga J; Costa F; Gomez H; Hudis CA; Rapoport B; Roche H; Schwartzberg LS; Petrenciuc O; Shan M; Gradishar WJ
Trials; 2013 Jul; 14():228. PubMed ID: 23876062
[TBL] [Abstract][Full Text] [Related]
6. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer.
Stemmler HJ; diGioia D; Freier W; Tessen HW; Gitsch G; Jonat W; Brugger W; Kettner E; Abenhardt W; Tesch H; Hurtz HJ; Rösel S; Brudler O; Heinemann V
Br J Cancer; 2011 Mar; 104(7):1071-8. PubMed ID: 21407218
[TBL] [Abstract][Full Text] [Related]
7. A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer.
Janni W; Sarosiek T; Karaszewska B; Pikiel J; Staroslawska E; Potemski P; Salat C; Brain E; Caglevic C; Briggs K; Desilvio M; Marini L; Papadimitriou C
Breast Cancer Res Treat; 2014 Feb; 143(3):493-505. PubMed ID: 24402830
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer.
Zhang J; Wang L; Wang Z; Hu X; Wang B; Cao J; Lv F; Zhen C; Zhang S; Shao Z
Cancer Biol Ther; 2015; 16(2):225-32. PubMed ID: 25648299
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG.
Smorenburg CH; de Groot SM; van Leeuwen-Stok AE; Hamaker ME; Wymenga AN; de Graaf H; de Jongh FE; Braun JJ; Los M; Maartense E; van Tinteren H; Nortier JWR; Seynaeve C
Ann Oncol; 2014 Mar; 25(3):599-605. PubMed ID: 24504445
[TBL] [Abstract][Full Text] [Related]
10. The efficiency and safety of low-dose apatinib combined with oral vinorelbine in pretreated HER2-negative metastatic breast cancer.
Huang JY; Chen XL; Xie XF; Song L; Chen LP; Lan XF; Bai X; Chen X; Du CW
Cancer Med; 2024 Apr; 13(8):e7181. PubMed ID: 38659376
[TBL] [Abstract][Full Text] [Related]
11. First-line bevacizumab-containing therapy for breast cancer: results in patients aged≥70 years treated in the ATHENA study.
Biganzoli L; Di Vincenzo E; Jiang Z; Lichinitser M; Shen Z; Delva R; Bogdanova N; Vivanco GL; Chen Z; Cheng Y; Just M; Espié M; Vinholes J; Hamm C; Crivellari D; Chmielowska E; Semiglazov V; Dalenc F; Smith I
Ann Oncol; 2012 Jan; 23(1):111-118. PubMed ID: 21444356
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer.
O'Shaughnessy JA; Kaufmann M; Siedentopf F; Dalivoust P; Debled M; Robert NJ; Harbeck N
Oncologist; 2012; 17(4):476-84. PubMed ID: 22418569
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine and Vinorelbine as an All-Oral Chemotherapy in HER2-Negative Locally Advanced and Metastatic Breast Cancer.
Gampenrieder SP; Bartsch R; Matzneller P; Pluschnig U; Dubsky P; Gnant MX; Zielinski CC; Steger GG
Breast Care (Basel); 2010; 5(3):158-162. PubMed ID: 21048830
[TBL] [Abstract][Full Text] [Related]
14. Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study.
Freyer G; Martinez-Jañez N; Kukielka-Budny B; Ulanska M; Bourgeois H; Muñoz M; Morales S; Calero JB; Cortesi L; Pintér T; Palácová M; Cherciu N; Petru E; Ettl J; de Almeida C; Villanova G; Raymond R; Minh CTT; Rodrigues A; Cazzaniga ME
Breast; 2024 Apr; 74():103681. PubMed ID: 38377732
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of utidelone plus capecitabine in advanced first-line therapy for metastatic breast cancer: A multicenter real-world study.
Bi P; Wang X; Liu R; Li X; Wei S; Zhao J; Tan X; Zhang F; Mao Q; Zhang Y; Tang B; Xun X; Guo R; Zheng K; Zhou S; Tang S
Surg Open Sci; 2023 Dec; 16():171-183. PubMed ID: 38026829
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA.
Zhu A; Yuan P; Hu N; Li M; Wang W; Wang X; Yue J; Wang J; Luo Y; Ma F; Zhang P; Li Q; Xu B; Cao S; Lippi G; Naito Y; Osman MA; Marta GN; Franceschini G; Orlandi A
Cancer Biol Med; 2021 May; 18(3):875-87. PubMed ID: 34037346
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy in Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: An Overview.
Andreopoulou E; Sparano JA
Curr Breast Cancer Rep; 2013 Mar; 5(1):42-50. PubMed ID: 23440080
[TBL] [Abstract][Full Text] [Related]
18. A Pilot Study of the Combination of Entinostat with Capecitabine in Advanced Breast Cancer.
Millard T; Brenin C; Humphrey C; Dhakal A; Falkson C; Petroni G; Wages NA; Dillon P
Int J Breast Cancer; 2024; 2024():5515966. PubMed ID: 38356965
[TBL] [Abstract][Full Text] [Related]
19. Oral vinorelbine to treat women with ectopic pregnancy: a phase 1 clinical safety and tolerability study.
Chowdary P; Hastie R; Lino T; Middleton A; Capes G; Humphries A; Abed-Ali A; Anderson M; Mol BWJ; Horne A; Lim E; Andrew P; Brownfoot F; Tong S
Fertil Steril; 2023 Sep; 120(3 Pt 2):695-696. PubMed ID: 37245616
[No Abstract] [Full Text] [Related]
20. Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.
Chan A; Conte PF; Petruzelka L; Tubiana-Mathieu N; Ganju V; Llombart A; Espie M; Majois F; Gil MG; Vaissiere N; Villanova G
Anticancer Res; 2013 Jun; 33(6):2657-64. PubMed ID: 23749924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
